Gas gangrene is synonymous with myonecrosis and is a highly lethal infection of deep soft tissue, caused by Clostridium species, with Clostridium perfringens being the most common. Clostridial myonecrosis historically was a common war wound infection with an incidence of 5%, but with improvement in wound care, antisepsis and the use of antibiotics, the incidence has fallen to 0.1% of war-related wound infections since the Vietnam war era. Puncture wounds and surgical wounds, especially GI surgeries done on the biliary tract or intestinal surgeries, are causes of clostridial infections due to inadvertent inoculation of the surgical wound with gut bacteria.
Clostridial infections usually arise in traumatized tissue but also can arise spontaneously. The infection involves deeper tissue such as a muscle which can lead to a rapidly spreading infection along tissue planes, and patients often present with sepsis. The infection may develop hours to weeks after the initial trauma and inoculation. The inoculation of the bacteria does not always cause gas gangrene, and there are host and organism factors that determine the progression to infection. Immunocompromised patients and those with local tissue hypoxia (due to trauma or poor vascular supply) are most at risk. The most common organisms that cause these infections are Clostridium perfringens, Clostridium septicum, and Clostridium histolyticum. C. septicum is the most common cause of spontaneous gas gangrene associated with G.I. abnormalities, such as colon cancer. C. perfringens and C. histolyticum are more commonly associated with post-traumatic infections.
More recently in the literature, Clostridium sordellii, an uncommon pathogen, has been reported to cause fatal shock syndrome and gas gangrene of the uterus after medical abortion with oral mifepristone and vaginal misoprostol. Clostridium sordellii is also on the rise associated with the use of black tar heroin injections, more commonly referred to as “popping.” This organism has also had increased incidence as the cause of deep tissue infections associated with childbirth and infections after gynecologic procedures including septic abortions, which can cause gas gangrene of the uterus.
In the United States, the incidence of myonecrosis is only about 1000 cases per year. In less developed countries with decreased access to healthcare and antibiotics, the incidence is probably higher, but the exact number is unknown. With the best of care, including early recognition, surgical care, antibiotic treatment, and hyperbaric oxygen therapy the overall mortality rate is 20% to 30% and in some studies as low as 5% to 10%; however, if not treated the disease has a 100% fatality. Host factors such as an immunocompromised state, diabetes mellitus, and spontaneous infections can have higher mortality rates of 67% or higher. If the infection involves the abdominal soft tissue or chest wall, the mortality rate can be as high as 60% compared to extremity infections with more favorable mortality of 5% to 30%.
C. perfringens cause 80% to 90%, of gas gangrene cases, but other species can cause infection. In order of prevalence, they are Clostridium novyi (40%), C. septicum (20%), C. histolyticum (10%), Clostridium bifermentans (10%), Clostridium fallax (5%), and C. sordellii. These organisms are in the soil and organic waste especially if contaminated with fecal material.
Health care workers should suspect gas gangrene if anaerobic gram-positive bacilli are present in a wound with necrosis of soft tissue and muscle. The organisms produce a gas identifiable on x-ray or CT scans. Only about 5% of the wounds colonized with clostridial organisms will develop an infection. Therefore, host factors and anatomic location of inoculation of the organisms help determine whether the bacteria will develop into a clostridial myonecrosis infection. For example, a deep penetrating wound into muscle tissue in which the host is immunocompromised is more likely to develop infection, compared to a host with a healthy immune system and good nutritional status. More open superficial wounds are less likely to become infected especially if properly cleaned and dressed compared to deeper penetrating wounds or wounds with crush injury and tissue ischemia.
The clostridial organisms produce alpha and theta toxins that cause extensive tissue damage. The infection can spread quickly, and within a matter of several hours, the patient may develop overwhelming shock, sepsis, and death. Tissue that is better oxygenated with 70mmHg oxygen tension will inhibit the organism growth because clostridial species are facultative anaerobes. A facultative anaerobe is an organism that makes ATP by aerobic respiration if oxygen is present but can switch to fermentation if oxygen is absent. If the oxygen tension of the tissue is less than 30 mm Hg, then the clostridial organisms will grow more quickly. The infection can develop slowly over weeks or rapidly over hours depending on the oxygen tension of the tissue and the amount of organism inoculated.
The virulence of the organism depends on the exotoxins produced; Clostridium perfringens is the most pathologic with 17 known toxins, with the most toxic being the alpha toxin, a lecithinase. Alpha toxin is a phospholipase (lecithinase) that breaks down cell membranes triggering platelet aggregation, thrombosis, and histamine release. Also present are collagenase, hyaluronidase, hemagglutinins, and hemolysins. Theta toxins cause direct vascular injury and breakdown of leukocytes causing blunted host inflammatory response to the infection. Collagenase breaks down connective tissue allowing the rapid spread of the organism across tissue planes. This is one of the main reasons that the infection can cross over connective tissue plains, spreading into the deeper muscle tissues.
The Gram stain of Clostridium will show large gram-positive rods with a paucity of leukocytes (as is typical of anaerobic infections).
Common toxins produced by C. perfringens:
Patients with gas gangrene (myonecrosis) present with signs of infection such as fever, chills, pain, and less superficial inflammation at the site of infection than one would expect given the deep penetrating nature of these infections. The condition of the patient can rapidly progress to sepsis and death if not treated aggressively. The wound discharge is often dishwater looking with a musty order. It can involve the vasculature that supplies large areas of infected tissue leading to necrosis of the subcutaneous fat down to the fascia and extends into the deeper muscle. If the nerves are damaged, the severity of the pain is less than expected for the extent of infection. The drainage from the necrotic tissue often has a dishwater appearance and musty order.
Signs of severe sepsis include septic shock, adult respiratory distress syndrome, disseminated intravascular coagulation, and hemolysis which may cause hemolytic anemia are often how patients present. Any patient with a cellulitis infection who develops additional signs of crepitus secondary to gas in the tissue and necrotic or dusky looking skin should be evaluated for gas gangrene.
Immediate workup of a patient with suspected gas gangrene includes: CBC, CMP, urinalysis, PT, APTT, blood and wound cultures. Additional blood tests such as ABG, lactic acid, and pre-calcitonin can be helpful in the evaluation of sepsis which is often present in gas gangrene. Common imaging studies include x-rays, CT scan of the infected body part, and ultrasound. These can be helpful in identifying the extent of the infection, abscess, and gas in the tissues. Extensive lab and imaging should not delay definitive surgical debridement of the necrotic tissue. A deep-wound aerobic and anaerobic culture at the time of the initial surgical debridement can help determine the causative organism and direct antibiotic therapy.
Because the infection is rapidly progressive, it is important to treat patients aggressively with antibiotics, early surgical consultation with debridement, intravenous fluid resuscitation, ICU monitoring, and adjuvant hyperbaric oxygen therapy.
It is important to get early surgical consultation without delay as this is a true surgical emergency. Providers should not delay antibiotics to get cultures, but should begin empiric treatment with antibiotics. Reasonable broad-spectrum coverage includes vancomycin and tazobactam or a carbapenem or ceftriaxone with metronidazole. If the provider suspects gas gangrene or a necrotising soft tissue infection, then penicillin plus clindamycin should be added which will also treat group A streptococcal necrotizing fasciitis. Clindamycin should be strongly considered because it inhibits the synthesis of clostridial exotoxins and will lessen the systemic effects of these toxins. Because clindamycin is bacteriostatic and not bacteriocidal, it should be used in conjunction with a second anti-microbial such as penicillin.
Fasciotomy may be necessary to relieve compartment pressures. As the infection progresses into deep tissue along and under the fascia tissue compartment pressures increase, which perpetuates further tissue ischemia and necrosis. Surgical debridement should focus on removing all the necrotic tissue, and foreign bodies such as soil, debris, and shrapnel. It is also important to irrigate the wounds with copious amounts of sterile normal saline.
Hyperbaric oxygen therapy should be added to standard therapy of antibiotics and surgical debridement to help improve survival. It is important to have coordinated care of these critically ill patients with an intensivist, general surgeon, orthopedic surgeon, urologist (in the setting of Fournier’s gangrene of the testicles and perineal structures), gynecologist (in the setting of uterine gas gangrene), infectious disease specialist, hematologist/oncologist, gastroenterologist (in the setting of spontaneous gas gangrene), and hyperbaric oxygen therapy specialist. The flow of consultation starts with usually an emergency department provider and early recognition of the disease.
Early IV antibiotics with early surgical debridement followed by hyperbaric oxygen therapy can salvage patients with an otherwise nearly always fatal disease. Intravenous antibiotics and early surgical debridement of the necrotic tissue reduce fatality rate to about 30%. With the addition of hyperbaric oxygen therapy, this can be reduced down to 5 to 10%. Hyperbaric oxygen therapy helps by halting exotoxin production by the bacteria, helps to improve the bactericidal effect of the antibiotic, treats the tissue ischemia, improves reperfusion injury of the tissue, and promotes the activation and migration of stem cells and polymorphonuclear cells. Additionally, hyperbaric oxygen induces vasoconstriction reducing tissue edema, while augmenting oxygenation. The oxygen tension of the tissue increases by a factor of 1000 and this increased oxygen in the tissue helps to resolve hypoxia, improve cellular activity, inhibit bacterial growth, and affect cytokinesis that increases migration of neutrophils to the injured tissue. Hyperbaric oxygen also increases the production of growth factors such as vascular epidermal growth factor (VEGF) which induces neovascularization and tissue repair with capillary budding. This is recognized clinically as increased granulation tissue formation and is usually seen after several hyperbaric oxygen treatments.
Hyperbaric oxygen therapy involves placing the patient in a pressurized chamber which can be mono-place (single patient) or multi-place (multiple patients treated at the same time). The mono-place chamber can only treat one patient at a time, and the attendant is outside of the chamber with specialized equipment and pumps to run IVs and even mechanical ventilation equipment through ports in the chamber door or wall. The disadvantage of this setup is that it limits the therapies available in the chamber and if the patient requires direct contact with the attendant, the chamber has to be depressurized, and the patient is taken out of the chamber. The multi-place chamber has the added benefit of being able to treat multiple patients at the same time, and the attendant is in the chamber with the patients allowing easier access to the patient for ventilator support, IV therapy, placement of a chest tube, or needle decompression of a pneumothorax. The treatment pressure for gas gangrene is 3 atmospheres absolute (ATA). The patient will have air brakes about every half hour to help reduce the risk of oxygen toxicity. These air brakes are usually 5 to 10 minutes in duration. The total duration of the treatment at pressure is usually about 90 minutes with 10 minutes for descent and 10 minutes for the ascent.
When treating gas gangrene the treatments start twice a day for the first 5 to 10 treatments, reducing to once daily treatments when stabilized. Continuing hyperbaric oxygen therapy beyond the initial stabilization can speed healing of tissue and preparation for eventual tissue grafting that is often necessary to close the large defects left after surgical debridement of dead tissue. The risk of hyperbaric oxygen therapy includes oxygen toxicity which can cause seizures, hypoglycemia especially in insulin-dependent diabetics, and barotrauma which can affect the ears, lungs or any gas-filled structures, such as the stomach, and gas embolism. These complications are rare, except for ear barotrauma which occurs approximately 43% of the time (84% of these are minor injection of the tympanic membrane).
Providers should consider the use of negative pressure wound dressing therapy once adequate surgical debridement has resolved ongoing tissue necrosis.
Patients with gas gangrene will need daily or repeated surgical debridement until the necrotizing infection is controlled, receive twice-daily hyperbaric oxygen therapy until tissue necrosis stops and signs of tissue recovery with granulation tissue formation occur. The patient will also need ongoing intensive care and may require hemodialysis for renal failure and extracorporeal membrane oxygenation (ECMO) for patients with severe adult respiratory distress syndrome (ARDS).
Once the infection resolves, many of these patients will require further wound care often with negative pressure wound therapy and advanced tissue regeneration techniques and plastic surgical therapies such as skin grafting and flap procedures to close the surgical wounds. Many patients with gas gangrene required prolonged ICU stays, followed by prolonged rehab to improve survival and restore function. Many patients will require transfer to a long-term care facility for ongoing wound care, sometimes hyperbaric oxygen therapy, and restorative rehab programs with physical therapy and occupational therapy.
To enhance patient survival and reduce morbidity in gas gangrene, this diagnosis should be high on the differential if patient present with infection with signs of necrotic tissue, sepsis, or if gas is present in the tissue. It is important to diagnose early, consult surgery for emergent debridement, and transfer patients with gas gangrene to facilities that have the capability of taking care of such ill patients. They require coordinated care between surgery, intensive care, and hyperbaric oxygen/wound care.
Best outcomes are achieved with coordinated care between multiple specialties and intensive care in a facility with personnel competent in the care of such critically ill patients. Care has to be coordinated between the surgeons doing the debridements, the wound care/hyperbaric oxygen providers and the intensivist. Photo documentation in the electronic health record helps improve coordination of care. The surgical team can take pictures in the operating room, and the wound care team can also take pictures when doing dressing changes. This helps nurses and other specialties, such as plastic surgery and infectious disease know the progress and helps guide decisions. Rehabilitation should start as soon as the patient is able, reducing the risk of blood clots and muscle atrophy. The care team effort must be coordinated so that everyone is on the same page regarding expectations of outcomes. There needs to be peer review and evaluation of team performance for the improvement of patient care in a non-hostile and supportive manner so that all team members are able and willing to contribute to improved patient care.
|||Takehara M, [Host Defense against Bacterial Infection and Bacterial Toxin-induced Impairment of Innate Immunity]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2018 [PubMed PMID: 30270267]|
|||Stevens DL,Aldape MJ,Bryant AE, Life-threatening clostridial infections. Anaerobe. 2012 Apr [PubMed PMID: 22120198]|
|||Dempsey A, Serious infection associated with induced abortion in the United States. Clinical obstetrics and gynecology. 2012 Dec [PubMed PMID: 23090457]|
|||Stevens DL,Bryant AE, Necrotizing Soft-Tissue Infections. The New England journal of medicine. 2017 Dec 7 [PubMed PMID: 29211672]|
|||Shindo Y,Dobashi Y,Sakai T,Monma C,Miyatani H,Yoshida Y, Epidemiological and pathobiological profiles of Clostridium perfringens infections: review of consecutive series of 33 cases over a 13-year period. International journal of clinical and experimental pathology. 2015 [PubMed PMID: 25755747]|
|||Lehnhardt M,Homann HH,Daigeler A,Hauser J,Palka P,Steinau HU, Major and lethal complications of liposuction: a review of 72 cases in Germany between 1998 and 2002. Plastic and reconstructive surgery. 2008 Jun [PubMed PMID: 18520866]|
|||Takazawa K,Otsuka H,Nakagawa Y,Inokuchi S, Clinical Features of Non-clostridial Gas Gangrene and Risk Factors for In-hospital Mortality. The Tokai journal of experimental and clinical medicine. 2015 Sep 20 [PubMed PMID: 26369267]|
|||Srivastava I,Aldape MJ,Bryant AE,Stevens DL, Spontaneous C. septicum gas gangrene: A literature review. Anaerobe. 2017 Dec [PubMed PMID: 28780428]|
|||[PubMed PMID: 17127198]|
|||[PubMed PMID: 24563915]|
|||[PubMed PMID: 30243450]|
|||[PubMed PMID: 29571810]|
|||[PubMed PMID: 1880179]|
|||[PubMed PMID: 27036998]|
|||[PubMed PMID: 18034207]|
|||[PubMed PMID: 8086576]|
|||[PubMed PMID: 30282543]|
|||[PubMed PMID: 26631369]|
|||[PubMed PMID: 26603791]|
|||[PubMed PMID: 22670554]|
|||[PubMed PMID: 30276115]|
|||[PubMed PMID: 10333449]|
|||[PubMed PMID: 29180205]|
|||[PubMed PMID: 21146022]|
|||[PubMed PMID: 2043237]|
|||[PubMed PMID: 29763178]|